Bayer to pay $160M as part of Onyx settlement

Bayer and Onyx Pharmaceuticals have resolved a longstanding dispute over the rights to a Nexavar follow-up drug. Bayer will pay $160 million plus royalties and give co-marketing rights to Onyx in return for control of the new drug's development and commercialization. Their partnership on Nexavar is mostly unchanged, the companies said. Release | News

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.